FY2026 Earnings Estimate for Alumis Issued By HC Wainwright

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for Alumis in a research note issued to investors on Friday, May 23rd. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($3.25) for the year. HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.

Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.47) by ($0.35).

ALMS has been the subject of several other reports. Oppenheimer reduced their price target on Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $24.86.

Alumis Stock Performance

NASDAQ:ALMS traded down $0.21 during trading hours on Monday, reaching $3.70. The company's stock had a trading volume of 155,969 shares, compared to its average volume of 376,271. The stock has a 50 day moving average price of $5.53 and a two-hundred day moving average price of $6.54. Alumis has a 12 month low of $3.18 and a 12 month high of $13.53.

Institutional Investors Weigh In On Alumis

Large investors have recently made changes to their positions in the stock. Corebridge Financial Inc. lifted its position in Alumis by 53.0% during the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company's stock worth $65,000 after acquiring an additional 3,693 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after purchasing an additional 3,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock valued at $77,000 after buying an additional 4,926 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis in the fourth quarter valued at approximately $79,000. Finally, Rhumbline Advisers increased its holdings in Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after buying an additional 2,949 shares during the period.

Insider Activity at Alumis

In related news, major shareholder Foresite Labs, Llc acquired 20,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were purchased at an average price of $4.34 per share, for a total transaction of $86,800.00. Following the completion of the acquisition, the insider now directly owns 4,247,670 shares in the company, valued at $18,434,887.80. The trade was a 0.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martin Babler acquired 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was bought at an average cost of $6.44 per share, with a total value of $100,786.00. Following the completion of the transaction, the chief executive officer now directly owns 106,454 shares in the company, valued at $685,563.76. The trade was a 17.23% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 397,044 shares of company stock valued at $1,891,895 in the last ninety days.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.